ZBIO insider trading
HealthcareZenas BioPharma, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Zenas BioPharma, Inc.
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Company website: zenasbio.com
ZBIO insider activity at a glance
FilingIQ has scored 74 insider transactions for ZBIO since Sep 13, 2024. The most recent filing in our index is dated Apr 29, 2026.
Across the full history, 46 open-market purchases
and 0 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on ZBIO insider trades is 62.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest ZBIO Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading ZBIO
Frequently asked
- How many insider trades does FilingIQ track for ZBIO?
- FilingIQ tracks 74 Form 4 insider transactions for ZBIO (Zenas BioPharma, Inc.), covering filings from Sep 13, 2024 onwards. 7 of those were filed in the last 90 days.
- Are ZBIO insiders net buyers or net sellers?
- Across the full Form 4 history for ZBIO, 46 transactions (62%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does ZBIO insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is ZBIO in?
- Zenas BioPharma, Inc. (ZBIO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.45B.
Methodology & sources
Every ZBIO insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.